I do have a question - Is the foundation providing funding for products that aren’t registered by the WHO yet?
I would imagine that should the trial be a success, then we may get some financial help regarding payment of the courses.
To the question of why is the release of the trial timetable important....
Well the market likes certainty, not plans. If the company comes out and states that the local government has approved the trial and the trial is about to start, then it will be game on. I have been of the opinion for months that a significant SP reaction will take place.
Even at current prices EMS has a market cap of just over $20m, has $6m in the bank, and are about to self-fund a phase III trial on a product that already works, that involves an alternative delivery system that has been shown to be more effective than the alternative. Still seems like an incredible risk reward to me.
EMS Price at posting:
6.5¢ Sentiment: None Disclosure: Held
